iCAD (NASDAQ:ICAD) Stock Price Passes Above Two Hundred Day Moving Average of $1.51

iCAD, Inc. (NASDAQ:ICAD) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.51 and traded as high as $1.68. iCAD shares last traded at $1.56, with a volume of 103,749 shares trading hands.

Wall Street Analyst Weigh In

Separately, StockNews.com raised iCAD from a “sell” rating to a “hold” rating in a research report on Thursday, August 22nd.

iCAD Stock Performance

The stock’s fifty day simple moving average is $1.45 and its two-hundred day simple moving average is $1.51. The company has a market cap of $41.93 million, a price-to-earnings ratio of -13.17 and a beta of 1.51.

iCAD (NASDAQ:ICAD) last posted its quarterly earnings results on Tuesday, August 13th. The technology company reported ($0.07) EPS for the quarter. The business had revenue of $5.03 million during the quarter. iCAD had a negative net margin of 15.67% and a negative return on equity of 13.59%.

Institutional Investors Weigh In On iCAD

Large investors have recently added to or reduced their stakes in the company. Salem Investment Counselors Inc. acquired a new stake in iCAD in the first quarter valued at $119,000. Perritt Capital Management Inc lifted its position in shares of iCAD by 14.2% during the second quarter. Perritt Capital Management Inc now owns 159,900 shares of the technology company’s stock worth $208,000 after purchasing an additional 19,917 shares during the last quarter. First Eagle Investment Management LLC increased its holdings in iCAD by 3.2% in the first quarter. First Eagle Investment Management LLC now owns 701,525 shares of the technology company’s stock valued at $1,129,000 after buying an additional 22,000 shares during the last quarter. AMH Equity Ltd acquired a new stake in iCAD during the first quarter valued at approximately $207,000. Finally, Virtu Financial LLC raised its stake in iCAD by 55.6% during the first quarter. Virtu Financial LLC now owns 21,286 shares of the technology company’s stock valued at $34,000 after buying an additional 7,604 shares in the last quarter. 24.61% of the stock is owned by institutional investors and hedge funds.

About iCAD

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.